Filing summary: Unum Therapeutics Inc. — Q2 2018 Form 10-Q
Entity discrepancy: The request identifies Cogent Biosciences, Inc., but the supplied filing is for Unum Therapeutics Inc. This summary reflects the supplied Unum filing, for the quarter and six months ended June 30, 2018, filed August 13, 2018.
Business context and reporting period
Unum was a clinical-stage biopharmaceutical company developing ACTR engineered T-cell immunotherapies used with tumor-specific antibodies. It had no approved products and generated no product-sales revenue; reported revenue came from its Seattle Genetics collaboration. The unaudited statements cover Q2 and the first half of 2018, with comparative periods in 2017.
Financial performance and liquidity
| Metric (USD millions, except per-share data) | Q2 2018 | Q2 2017 | H1 2018 | H1 2017 |
|---|---|---|---|---|
| Collaboration revenue | 1.7 | 2.1 | 3.9 | 3.9 |
| Research and development expense | 9.1 | 7.1 | 17.3 | 14.1 |
| General and administrative expense | 2.0 | 1.0 | 3.0 | 1.9 |
| Operating loss | (9.4) | (6.0) | (16.4) | (12.1) |
| Net loss | (9.0) | (5.9) | (15.8) | (11.8) |
| Basic and diluted net loss per share | (0.31) | (0.58) | (0.80) | (1.16) |
| Cash used in operating activities | Not presented quarterly | Not presented quarterly | (15.9) | (13.0) |
At June 30, cash and cash equivalents were $46.7 million and marketable securities were $47.7 million, totaling $94.4 million. Current assets were $97.1 million and current liabilities $24.8 million; working capital was $72.3 million. Total liabilities were $26.0 million. No debt was outstanding; a bank facility provided up to $15.0 million of undrawn borrowing capacity, secured by substantially all assets other than intellectual property.
H1 investing activities used $35.4 million, mainly reflecting purchases of marketable securities; financing provided $69.8 million, principally from the IPO and concurrent private placement. Cash, cash equivalents and restricted cash increased $18.4 million to $48.0 million. The company reported no material debt-related interest-rate exposure.
Changes versus comparable periods
- Q2 collaboration revenue declined about 20% year over year; H1 revenue was essentially flat. R&D expense rose about 28% in Q2 and 23% in H1, reflecting increased ACTR707 and SEA-BCMA trial and manufacturing activity, partly offset by lower ACTR087/rituximab manufacturing costs.
- G&A expense increased about 104% in Q2 and 59% in H1, including higher public-company, professional-services, personnel and stock-compensation costs.
- Net loss widened about 54% in Q2 and 34% in H1. Loss per share narrowed, principally in a period with substantially more weighted-average shares following the IPO and preferred-stock conversion.
- The April 2018 IPO and concurrent Seattle Genetics private placement materially strengthened liquidity. The IPO and follow-on option shares generated $63.9 million net proceeds in total; the private placement raised $5.0 million. Outstanding preferred stock converted into common stock at the IPO closing.
Outlook, management commentary, risks and unusual items
- Management expected cash, cash equivalents and marketable securities to fund operating expenses and capital expenditures through at least December 2019, excluding available bank borrowings. The financial-statement note separately describes runway of at least 12 months from the August 13 issuance date. Management cautioned that estimates depend on assumptions and capital could be used sooner than expected.
- The filing states existing resources, including the available credit facility, would not fund two planned studies: an ACTR087/rituximab Phase II study in patients previously treated with CD19 CAR-T therapy and an ACTR707/trastuzumab Phase I study. Additional funding would be required. Management anticipated rising clinical, manufacturing, staffing and public-company costs and ongoing operating losses.
- Clinical milestones cited: updated ACTR087/rituximab data, including preliminary cohort-expansion data, expected by year-end 2018 or early 2019; initial ACTR707/rituximab and ACTR087/SEA-BCMA data expected in Q4 2018; and initiation of the ACTR707/trastuzumab Phase I trial expected by year-end 2018. These are expectations, not guarantees.
- Safety is a major risk. The ACTR087/rituximab Phase I trial had been placed on FDA clinical hold in December 2017 and the hold was removed in February 2018 after information was submitted. The filing describes severe cytokine-release syndrome and neurotoxicity, including a fatal neurotoxicity event, and fatal sepsis cases among treated patients. Protocol and dosing changes were made; further serious events could lead to additional holds or trial termination.
- Unum adopted ASC 606 in 2018 using the modified retrospective method. The adoption increased opening deferred revenue and accumulated deficit by $6.2 million. For H1 2018 it reduced reported collaboration revenue and increased net loss by $1.3 million versus the prior revenue standard; Q2 revenue was lower by $0.9 million. Remaining Seattle Genetics collaboration performance obligations were estimated at approximately $74.0 million, expected to be recognized through December 2022.
- Other commitments include $9.5 million of future minimum operating-lease payments and $1.7 million of non-cancelable manufacturing commitments over the following 12 months. No material legal proceedings were reported. Disclosure controls were judged effective at a reasonable-assurance level, with no material Q2 change in internal control over financial reporting.
Most important facts for investors to verify
- Confirm the issuer: the supplied filing is Unum Therapeutics, not Cogent Biosciences.
- Review the clinical updates and safety disclosures, especially ACTR087/rituximab adverse events, FDA oversight and the impact of protocol changes.
- Track actual cash burn against the stated runway and the funding needed for the two planned trials; distinguish cash and securities from the undrawn, secured credit facility.
- Assess Seattle Genetics collaboration revenue under ASC 606, including the $74.0 million remaining performance obligation and the timing assumptions for recognition.
- Monitor clinical enrollment, manufacturing capacity and supply dependencies, collaboration terms, and potential dilution from future financing and equity awards.